By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Otsuka Pharmaceutical Development & Commercialization, Inc. 

100 Overlook Drive

Princeton  New Jersey  08540  U.S.A.
Phone: 609-452-2922 Fax: 609-452-0794


SEARCH JOBS


Industry
Pharmaceutical






Company News
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016 9:46:21 AM
Otsuka Pharmaceutical Development & Commercialization, Inc. Release: FDA Approves Labeling Update Of REXULTI (brexpiprazole) For Maintenance Treatment Of Schizophrenia 9/26/2016 10:53:43 AM
Otsuka Pharmaceutical Development & Commercialization, Inc. To Present Scientific Data At American Psychiatric Association Annual Meeting 5/16/2016 11:14:48 AM
Otsuka Pharmaceutical Development & Commercialization, Inc. Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 6/11/2014 9:53:27 AM
Otsuka Pharmaceutical Development & Commercialization, Inc.'s Kidney Disease Drug Faces Setback 8/30/2013 6:51:47 AM
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring 2/25/2009 7:26:41 AM
Xceleron to Provide Otsuka Pharmaceutical Development & Commercialization, Inc. with META-IDâ„¢ Services to Obtain Critical Metabolism Information at Phase I. 11/18/2008 2:43:34 PM
FDA (JOBS) Advisory Committee Recommends Approval of Otsuka Pharmaceutical Development & Commercialization, Inc.'s (JOBS) Tolvaptan, an Investigational Treatment for Hyponatremia 6/26/2008 6:40:34 AM
//-->